Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• Martine Rothblatt sold 9,500 shares of United Therapeutics on May 6 at an average price of $589.52 for about $5.6M, reducing her stake by 19% to 40,513 shares valued near $23.9M.
• Q1 results missed estimates — EPS $5.82 vs. ~$7.00 and revenue $781.5M vs. $797.4M — and the stock fell roughly 4.6% to $569.18 on heavy trading after the report.
• Despite the earnings miss and recent insider sales, analysts remain largely positive (11 Buy, 2 Hold) with an average price target near $619, supported by pipeline optimism around Tyvaso/IPF and ralinepag.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $589.52, for a total transaction of $5,600,440.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $23,883,223.76. This represents a 19.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

United Therapeutics Stock Down 4.6%

Shares of NASDAQ UTHR traded down $27.58 during midday trading on Thursday, hitting $569.18. The stock had a trading volume of 830,871 shares, compared to its average volume of 485,002. The business's 50 day moving average is $548.25 and its 200-day moving average is $500.41. The company has a market cap of $24.05 billion, a P/E ratio of 20.40, a PEG ratio of 1.63 and a beta of 0.60. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company's quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.63 EPS. As a group, analysts expect that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC increased its holdings in United Therapeutics by 2.8% during the first quarter. Parallel Advisors LLC now owns 1,056 shares of the biotechnology company's stock valued at $626,000 after buying an additional 29 shares during the last quarter. SEB Asset Management AB purchased a new stake in United Therapeutics during the first quarter valued at approximately $10,514,000. Swiss National Bank increased its holdings in United Therapeutics by 2.0% during the first quarter. Swiss National Bank now owns 120,055 shares of the biotechnology company's stock valued at $71,190,000 after buying an additional 2,320 shares during the last quarter. AIA Group Ltd increased its holdings in United Therapeutics by 20.9% during the first quarter. AIA Group Ltd now owns 2,415 shares of the biotechnology company's stock valued at $1,432,000 after buying an additional 417 shares during the last quarter. Finally, Arjuna Capital increased its holdings in United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after buying an additional 18 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on UTHR. Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research report on Thursday, March 12th. HC Wainwright increased their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a research report on Tuesday, March 31st. TD Cowen increased their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a research report on Monday, March 30th. Jefferies Financial Group restated a "buy" rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Wells Fargo & Company set a $735.00 price objective on shares of United Therapeutics and gave the company an "overweight" rating in a research report on Thursday. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $619.42.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors are focusing on Tyvaso IPF data and the blockbuster potential of ralinepag, which helped shares rally after the Q1 report despite the miss; this pipeline optimism can support longer‑term valuation. Zacks: UTHR Q1 Earnings Miss, Shares Jump on Strong Outlook
• Positive Sentiment: Company highlighted continued clinical progress (including positive ADVANCE O results noted in the press release), which supports revenue growth potential beyond near‑term quarterly fluctuations. BusinessWire: Q1 2026 Financial Results
• Positive Sentiment: Expansion of a DPI/inhaled delivery partnership ecosystem tied to United Therapeutics activity has supportive implications for commercial reach and Tyvaso delivery options. Market reaction to related partnership news lifted peers and signals strategic optionality. Investing.com: MannKind Stock Surges on United Therapeutics Partnership
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly (from $707 to $701) but kept an "outperform" rating — a modest technical downgrade that still implies meaningful upside versus current levels. Benzinga: RBC Lowers Price Target
• Neutral Sentiment: Several analysts have raised targets in recent months (UBS, BofA, Cantor, Oppenheimer), leaving a mixed analyst landscape—some higher targets offset by occasional trims. Investors are parsing these conflicting signals. MarketBeat: UTHR Analyst Coverage
• Negative Sentiment: Q1 results missed estimates: EPS $5.82 vs. consensus near $7.00 and revenue of $781.5M below expectations — a clear near‑term earnings and top‑line disappointment that pressures the stock. Zacks: UTHR Misses Q1 Estimates
• Negative Sentiment: Significant insider sales: CEO and CFO sold multi‑million dollar stakes earlier in the week, which markets often view as a negative signal about near‑term insider conviction. SEC Filing: Insider Sales

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.